Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Health Canada has approved Paladin Labs's treatment for life-threatening digoxin toxicity, Digifab.
Subscribe to our email newsletter
DigiFab is an antidote for digoxin toxicity. It works by binding to digoxin and preventing it from working in the body.
Paladin Labs president and CEO Jonathan Ross Goodman said DigiFab provides an important opportunity to grow Paladin’s specialty and orphan franchise which includes Replagal, Elaprase and Antizol.
"Following approval, DigiFab will provide patients and physicians with a new option for the treatment digoxin poisoning," Goodman said.
Protherics has licensed DigiFab marketing rights to Paladin Labs in Canada.